Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  2008-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijrobp.2008.04.027PMID 18538948
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging

  2007cited by this paper
• Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126.

  2007cited by this paper
• 5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent

  2006cited by this paper
• Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.

  2006cited by this paper
• Differentiation and definition of vascular-targeted therapies.

  2005cited by this paper
• Tumor Dose Response to the Vascular Disrupting Agent, 5,6-Dimethylxanthenone-4-Acetic Acid, Using In vivo Magnetic Resonance Spectroscopy

  2005cited by this paper
• Patupilone Induced Vascular Disruption in Orthotopic Rodent Tumor Models Detected by Magnetic Resonance Imaging and Interstitial Fluid Pressure

  2005cited by this paper
• Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.

  2005cited by this paper
• Mechanisms of tumor vascular shutdown induced by 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA): Increased tumor vascular permeability

  2005cited by this paper
• Disrupting tumour blood vessels

  2005cited by this paper
• Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.

  2005cited by this paper
• Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor.

  2005cited by this paper
• Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model.

  2004cited by this paper
• Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

  2004cited by this paper
• Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice

  2004cited by this paper
• Vascular‐targeting therapies for treatment of malignant disease

  2004cited by this paper
• Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.

  2004cited by this paper
• Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials.

  2003cited by this paper
• Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.

  2002cited by this paper
• Vessel size imaging

  2001influential reference
• Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.

  1999cited by this paper
• Improved delineation of human brain tumors on MR images using a long‐circulating, superparamagnetic iron oxide agent

  1999cited by this paper
• Trends in cancer incidence and mortality in Scotland: description and possible explanations.

  1998cited by this paper
• United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition).

  1998cited by this paper
• NMR imaging of changes in vascular morphology due to tumor angiogenesis

  1998influential reference
• Method for image-based measurement of the reversible and irreversible contribution to the transverse-relaxation rate.

  1996cited by this paper
• Induction of apoptosis in proliferating human

  year unknowncited by this paper

• STING Agonists as Cancer Therapeutics

  2021cites this paper
• Differentiation of Cerebral Neoplasms with Vessel Size Imaging (VSI)

  2021cites this paper
• Magnetic Resonance Imaging for Translational Research in Oncology

  2019cites this paper
• Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes

  2018cites this paper
• Assessment of the direct effects of DDAH I on tumour angiogenesis in vivo

  2018cites this paper
• Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma

  2017cites this paper
• Investigating the role of tumour cell derived iNOS on tumour growth and vasculature in vivo using a tetracycline regulated expression system

  2016cites this paper
• Imaging the microvessel caliber and density: Principles and applications of microvascular MRI

  2015cites this paper
• Improving tumour heterogeneity MRI assessment with histograms

  2014cites this paper
• Vessel calibre—a potential MRI biomarker of tumour response in clinical trials

  2014cites this paper
• High-field small animal magnetic resonance oncology studies

  2014cites this paper
• Assessing breast cancer angiogenesis in vivo: which susceptibility contrast MRI biomarkers are relevant?

  2013cites this paper
• Vessel Size Imaging (VSI) by Robust Magnetic Resonance (MR) Relaxometry: MR-VSI of Solid Tumors in Correlation with Immunohistology and Intravital Microscopy

  2013cites this paper
• A Multi-Parametric Imaging Investigation of the Response of C6 Glioma Xenografts to MLN0518 (Tandutinib) Treatment

  2013cites this paper
• MRI measurements of vessel calibre in tumour xenografts: Comparison with vascular corrosion casting

  2012cites this paper
• Non‐invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts

  2012cites this paper
• Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using magnetic resonance imaging based vessel size imaging

  2012cites this paper
• Combretastatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging

  2012cites this paper
• Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas

  2011cites this paper
• Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.

  2011cites this paper
• A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.

  2011cites this paper
• MRI & MRS assessment of the role of the tumour microenvironment in response to therapy

  2011cites this paper
• Histogram analysis of the microvasculature of intracerebral human and murine glioma xenografts

  2011cites this paper
• Evaluation of magnetic resonance vessel size imaging by two‐photon laser scanning microscopy

  2010cites this paper
• The Use of Animal Models in the Assessment of Tumour Vascular Disrupting Agents (VDAs)

  2010cites this paper
• Lessons from Animal Imaging in Preclinical Models

  2010cites this paper
• Non‐Invasive Imaging of the Tumor Microenvironment

  2010cites this paper
• Quantitative contrast-enhanced MRI of the microvasculature

  2009cites this paper
• Two-photon microscopic imaging of neo-vasculature in atherosclerotic plaques and tumors

  2009cites this paper
• Current Awareness in NMR in Biomedicine

  2009cites this paper